Key differences at a glance Understanding GLP-1 medications GLP-1 (glucagon-like peptide-1) receptor agonists were originally developed for type 2 diabetes but have revolutionised obesity treatment
These nine companies are building on what Ozempic started, betting on pills instead of injections, drugs that spare muscle, and uses well beyond obesity
This cardiovascular protective effect is something other GLP-1 medications have not yet demonstrated at the same level, making Wegovy widely regarded by clinicians as the current gold-standard option specifically for obesity with cardiovascular risk
Perhaps their biggest effect on metabolism comes from their powerful insulin-stimulating effects
But realistic planning means understanding that discontinuation carries a high probability of significant weight regain
Research Peptide Access For Canadians interested in these compounds before regulatory approval, research peptide suppliers offer an alternative access pathway